AIDS Progression Reduced by Almost Two-Thirds with Protease Inhibitor Crixivan, Brazil Trial Shows

MAR-21-1997 11:41 FROM MHHD PUBLIC AFFAIRS TO 916199424979 P.001/006 Stephen H. Hull Manager, Public Affairs Worldwide Human Health Division 4,19 /9fle yfl Merck & Co., Inc. One Merck Drive PO Box 100. WS 18-56 Whitehouse Station, NJ 088890100 Tel + 908 423 3086 Fax: + 908 735 1194 or 1195 MERCK ape FAX TRANSMISSION Date: 3.II Total Pages: co lVxcAcc c.. V To: Tohv 4Mohn Loc: S cc Subj: 3;wonolL Stmrvr cc: - - -- ---.&----- --j---- -- - - _J__ -- - ----------.------ - r,----_ '8Iivwled Wse oCsW rwy 4ew, ckd. -ck sat osttckd. Prss ttit-s/ 400"4 6sk, e4k "wo C 4 kI Vfl4J (or, eaodil k) * S4,ot &wvcerav LCL~bP4Lc 'ixwivt 4 K it, 'cs cr rwe 4

/ 6

Actions

file_download Download Options Download this page PDF - Pages 1- Image - Page #6 Plain Text - Page #6

About this Item

Title
AIDS Progression Reduced by Almost Two-Thirds with Protease Inhibitor Crixivan, Brazil Trial Shows
Author
Merck Sharp & Dohme.
Canvas
Page #6
Publication
Merck Sharp & Dohme.
1997-03-21
Subject terms
press releases
Item type:
press releases

Technical Details

Link to this Item
https://name.umdl.umich.edu/5571095.0344.013
Link to this scan
https://quod.lib.umich.edu/c/cohenaids/5571095.0344.013/6

Rights and Permissions

The University of Michigan Library provides access to these materials for educational and research purposes, with permission from their copyright holder(s). If you decide to use any of these materials, you are responsible for making your own legal assessment and securing any necessary permission.

Manifest
https://quod.lib.umich.edu/cgi/t/text/api/manifest/cohenaids:5571095.0344.013

Cite this Item

Full citation
"AIDS Progression Reduced by Almost Two-Thirds with Protease Inhibitor Crixivan, Brazil Trial Shows." In the digital collection Jon Cohen AIDS Research Collection. https://name.umdl.umich.edu/5571095.0344.013. University of Michigan Library Digital Collections. Accessed June 11, 2025.
Do you have questions about this content? Need to report a problem? Please contact us.